← Back to Clinical Trials
Recruiting NCT06153303

NCT06153303 Internet-based ACT for Endometriosis and Chronic Pain

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06153303
Status Recruiting
Phase
Sponsor Skane University Hospital
Condition Endometriosis
Study Type INTERVENTIONAL
Enrollment 10 participants
Start Date 2024-01-01
Primary Completion 2026-10-01

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
Acceptance and commitment therapy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 10 participants in total. It began in 2024-01-01 with a primary completion date of 2026-10-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The primary aim of this study is to investigate the effect of Internet-delivered Acceptance and commitment therapy for endometriosis and chronic pain. A pilot study (no randomization; N=10) will be conducted to test the intervention and assessment procedures. The participants will go through an active internet-based ACT treatment focused on education about endometriosis and chronic pain, value-based exposure for avoided situations, and behavior change through exercises targeting the processes mindfulness, cognitive defusion and acceptance. The treatment is delivered on a safe internet platform. Participants have planned telephone contact with their assigned psychologist 2 times during the program and can also contact their psychologist via a message system in the platform and expect answer within 48 hours.

Eligibility Criteria

Inclusion Criteria: * verified endometriosis * age between 18-65 years * were fully examined medically and had received medical treatment if indicated * were able to be an active part of the rehabilitation process, regain functioning in different life areas and participate in treatment interventions for approximately 5 hours every week * stable dose of medication * able to read and write in Swedish * had access to a smart phone or computer with internet access Exclusion Criteria: * had acute or severe psychiatric disorders or symptoms that warranted designation as the primary disorder (ongoing substance dependence, untreated bipolar disorder, OCD, psychotic symptoms, severe depression, PTSD) * were actively abusing analgesic medications (including narcotics), alcohol or other drugs * had great difficulty to harbour and handle strong emotions that could lead to emotional outbursts or self-harming behavior * had health risks due to medical reasons; * had social or economic difficulties or lack of social support that hindered behavior change * current severe suicidal ideation that warranted immediate intervention (indicated by the MINI and a score of 3 to item 9 of the Patient Health Questionnaire 9-item version (PHQ9))

Contact & Investigator

Central Contact

Sophia Åkerblom, PhD

✉ sophia.akerblom@skane.se

📞 004646171520

Frequently Asked Questions

Who can join the NCT06153303 clinical trial?

This trial is open to female participants only, aged 18 Years or older, up to 65 Years, studying Endometriosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06153303 currently recruiting?

Yes, NCT06153303 is actively recruiting participants. Contact the research team at sophia.akerblom@skane.se for enrollment information.

Where is the NCT06153303 trial being conducted?

This trial is being conducted at Lund, Sweden.

Who is sponsoring the NCT06153303 clinical trial?

NCT06153303 is sponsored by Skane University Hospital. The trial plans to enroll 10 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology